Little information is available concerning adverse drug events (ADEs) in cardiac patients. Therefore, the investigators report the results of cardiac patients in an ADE surveillance program, with the intent of reducing the frequency of future events. All reported adverse drug reactions and medication errors in cardiac patients over a 5-year period at Brigham and Women's Hospital were reviewed.
View Article and Find Full Text PDFAMIA Annu Symp Proc
September 2007
At Brigham and Women's Hospital (BWH) in Boston, MA, we recently concluded a four year randomized, controlled study of the effect of electronic alerts on physician behavior in the prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). We found that the use of an electronic alert reduced the risk of DVT or PE at 90 days by 41%. Upon review of the instances where the recommended prophylaxis was not accepted, we designed enhancements to the alert.
View Article and Find Full Text PDFBackground: Many dispensing errors made in hospital pharmacies can harm patients. Some hospitals are investing in bar code technology to reduce these errors, but data about its efficacy are limited.
Objective: To evaluate whether implementation of bar code technology reduced dispensing errors and potential adverse drug events (ADEs).
We performed a direct observation prepost study to evaluate the impact of barcode technology on medication dispensing errors and potential adverse drug events in the pharmacy of a tertiary-academic medical center. We found that barcode technology significantly reduced the rate of target dispensing errors leaving the pharmacy by 85%, from 0.37% to 0.
View Article and Find Full Text PDFJt Comm J Qual Patient Saf
February 2006
Background: Hospital pharmacies dispense large numbers of medication doses for hospitalized patients. A study was conducted at an academic tertiary care hospital to characterize the incidence and severity of medication dispensing errors in a hospital pharmacy.
Methods: Direct observation of dispensing processes was undertaken to determine presence of errors with review by a physician panel to determine severity.
Study Objective: To evaluate the safety and efficacy of valganciclovir 450 mg/day for 6 months for cytomegalovirus (CMV) prophylaxis in renal transplant recipients.
Design: Single-center, retrospective analysis.
Setting: Urban, academic medical center.